Suppr超能文献

鉴定土拉弗朗西斯菌外膜蛋白 A(FopA)作为土拉菌病的保护性抗原。

Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

机构信息

Albany Medical College, Center for Immunology and Microbial Disease, Albany, NY 12208, USA.

出版信息

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.

Abstract

Francisella tularensis is a highly pathogenic gram negative bacterium that infects multiple sites in a host, including the skin and the respiratory tract, which can lead to the onset of a deadly disease with a 50% mortality rate. The live vaccine strain (LVS) of F. tularensis, while attenuated in humans but still virulent in mice, is not an option for vaccine use in the United States due to safety concerns, and currently no FDA approved vaccine exists. The purpose of the present work was to assess the ability of recombinant Francisella outer membrane protein A (FopA) to induce a protective response in mice. The gene encoding FopA from F. tularensis LVS was cloned and expressed in Escherichia coli. The resulting recombinant protein was affinity-purified from the E. coli outer membrane, incorporated into liposomes and administered to mice via multiple routes. FopA-immunized mice produced FopA-specific antibodies and were protected against both lethal intradermal and intranasal challenges with F. tularensis LVS. The vaccinated mice had reduced bacterial numbers in their lungs, livers and spleens during infection, and complete bacterial clearance was observed by day 28 post infection. Passive transfer of FopA-immune serum protected naïve mice against lethal F. tularensis LVS challenge, showing that humoral immunity played an important role in vaccine efficacy. FopA-immunization was unable to protect against challenge with the fully virulent SchuS4 strain of F. tularensis; however, the findings demonstrate proof of principle that an immune response generated against a component of a subunit vaccine is protective against lethal respiratory and intradermal tularemia.

摘要

弗氏耶尔森菌是一种高致病性革兰氏阴性菌,可感染宿主的多个部位,包括皮肤和呼吸道,从而导致一种致命疾病的发作,死亡率为 50%。活疫苗株(LVS)虽然在人类中减毒,但在小鼠中仍具有毒力,由于安全性问题,不能作为美国的疫苗选择,目前也没有获得 FDA 批准的疫苗。本研究旨在评估重组弗朗西斯氏菌外膜蛋白 A(FopA)在小鼠中诱导保护性反应的能力。从弗氏耶尔森菌 LVS 中克隆并在大肠杆菌中表达编码 FopA 的基因。从大肠杆菌外膜中亲和纯化得到的重组蛋白被包裹在脂质体中,并通过多种途径给予小鼠。FopA 免疫的小鼠产生了 FopA 特异性抗体,并能抵抗致死性皮内和鼻内弗氏耶尔森菌 LVS 挑战。感染期间,接种疫苗的小鼠肺部、肝脏和脾脏中的细菌数量减少,感染后第 28 天观察到完全清除细菌。FopA 免疫血清的被动转移可保护未感染的小鼠免受致死性弗氏耶尔森菌 LVS 挑战,表明体液免疫在疫苗效力中起重要作用。FopA 免疫不能预防完全毒力的 SchuS4 株弗氏耶尔森菌的挑战;然而,这些发现证明了一个原理,即针对亚单位疫苗成分产生的免疫反应对致死性呼吸道和皮内土拉菌病具有保护作用。

相似文献

引用本文的文献

4
Protective potential of outer membrane vesicles derived from a virulent strain of .源自. 强毒株的外膜囊泡的保护潜力
Front Microbiol. 2024 Mar 12;15:1355872. doi: 10.3389/fmicb.2024.1355872. eCollection 2024.

本文引用的文献

2
Tickborne infections in the southern United States.美国南部的蜱传感染。
Am J Med Sci. 2010 Sep;340(3):194-201. doi: 10.1097/MAJ.0b013e3181e93817.
10
Innate and adaptive immunity to Francisella.针对弗朗西斯菌的固有免疫和适应性免疫。
Ann N Y Acad Sci. 2007 Jun;1105:284-324. doi: 10.1196/annals.1409.014. Epub 2007 Apr 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验